Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Innovative research for a dog cancer treatment from the University of Missouri College of Veterinary Medicine has shown early ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

In the meantime, it’s important for you to be careful around Maurice as the chemo might make you more susceptible to diseases ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.

Based on the No. 1 podcast of the same name, “Scamanda” tells the story of Amanda Riley, whose tragic cancer tale captivated ...

In the meantime, it’s important for you to be careful around Maurice as the chemo might make you more susceptible to diseases ...

Washington, D.C. (7News) — LLS and IHOP have partnered for the 26th year in a row to raise money for Leukemia treatment and research. In honor of the partnership, Representatives from LLS and IHOP ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...